Patents by Inventor Robert C. Cuca
Robert C. Cuca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11464741Abstract: The present disclosure provides compositions having different dissolution profiles. In particular, the compositions are formulated by adjusting the types and/or amounts of excipients and/or surfactants, and the compositions are prepared by spray drying processes.Type: GrantFiled: May 27, 2015Date of Patent: October 11, 2022Assignee: SpecGX LLCInventors: Joseph M. Davis, Robert C. Cuca, Edward J. Beasley
-
Patent number: 9789057Abstract: A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 ?g to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL·hr.Type: GrantFiled: July 23, 2012Date of Patent: October 17, 2017Assignee: Perrigo Pharma International Designated Activity CompanyInventors: Thomas C. Riley, R. Saul Levinson, Robert C. Cuca, Elio Mariani
-
Publication number: 20150359743Abstract: The present disclosure provides compositions having different dissolution profiles. In particular, the compositions are formulated by adjusting the types and/or amounts of excipients and/or surfactants, and the compositions are prepared by spray drying processes.Type: ApplicationFiled: May 27, 2015Publication date: December 17, 2015Inventors: Joseph M. Davis, Robert C. Cuca, Edward J. Beasley
-
Publication number: 20130172279Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.Type: ApplicationFiled: July 25, 2012Publication date: July 4, 2013Applicant: DRUGTECH CORPORATIONInventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
-
Publication number: 20130102548Abstract: A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 ?g to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL·hr.Type: ApplicationFiled: July 23, 2012Publication date: April 25, 2013Applicant: DRUGTECH CORPORATIONInventors: Thomas C. Riley, R. Saul Levinson, Robert C. Cuca, Elio Mariani
-
Patent number: 8057433Abstract: A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.Type: GrantFiled: July 8, 2005Date of Patent: November 15, 2011Assignee: DrugTech CorporationInventors: Robert C. Cuca, Thomas C. Riley, R. Saul Levinson
-
Publication number: 20110276030Abstract: A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.Type: ApplicationFiled: July 8, 2005Publication date: November 10, 2011Applicant: DRUGTECH CORPORATIONInventors: Robert C. Cuca, Thomas C. Riley, R. Saul Levinson
-
Publication number: 20110251141Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.Type: ApplicationFiled: June 20, 2011Publication date: October 13, 2011Applicant: DRUGTECH CORPORATIONInventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
-
Publication number: 20080287408Abstract: A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated.Type: ApplicationFiled: April 18, 2008Publication date: November 20, 2008Applicant: DRUGTECH CORPORATIONInventors: Daniel J. Thompson, Robert C. Cuca, Thomas C. Riley, JR., Jonathan David Bortz
-
Publication number: 20080097388Abstract: A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.Type: ApplicationFiled: July 8, 2005Publication date: April 24, 2008Applicants: DRUGTECH CORPORATIONInventors: Robert C. Cuca, Thomas C. Riley, R. Saul Levinson
-
Publication number: 20080003262Abstract: A method for treating non-infectious inflammatory vulvovaginitis comprises administering to a vulvovaginal surface a pharmaceutical composition that comprises clindamycin in an amount of about 125 mg to about 400 mg per unit dose of the composition; wherein the composition is bioadhesive to the vulvovaginal surface, and upon application of the composition to the vulvovaginal surface the clindamycin is released over a period of about 3 hours to about 14 days. A related method comprises administering to a vulvovaginal surface a pharmaceutical composition comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, wherein the composition has at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. A pharmaceutical composition comprises (a) clindamycin or a pharmaceutically acceptable salt or ester thereof in a clindamycin equivalent amount of about 2.Type: ApplicationFiled: June 28, 2007Publication date: January 3, 2008Applicant: DrugTech CorporationInventors: R. Saul Levinson, Robert C. Cuca, Jonathan Bortz
-
Publication number: 20020187205Abstract: Multi-vitamin and mineral supplements for administration to non-lactating women, which comprise specific regimens of vitamins and minerals tailored to meet the physiological needs of said women. Methods for optimizing the health of women by providing multi-vitamin and mineral supplements which are specifically tailored to achieve optimal regulation of growth, maintenance and repair of body tissue during specific stages of life with minimal side effects. Methods for formulating a multi-vitamin and mineral supplement that optimize the health of a woman and which comprise identifying life stages which correlate to specific nutritional requirements as a result of varying physiological conditions during a lifetime and selecting specific types and optimal amounts of vitamins and minerals for said life stages.Type: ApplicationFiled: July 31, 2002Publication date: December 12, 2002Applicant: K-V Pharmaceutical CompanyInventors: George N. Paradissis, R. Saul Levinson, Robert C. Cuca, Patrick Paul Vanek
-
Patent number: 6488956Abstract: Multi-vitamin and mineral supplements for administration to non-lactating women, which comprise specific regimens of vitamins and minerals tailored to meet the physiological needs of said women. Methods for optimizing the health of women by providing multi-vitamin and mineral supplements which are specifically tailored to achieve optimal regulation of growth, maintenance and repair of body tissue during specific stages of life with minimal side effects. Methods for formulating a multi-vitamin and mineral supplement that optimize the health of a woman and which comprise identifying life stages which correlate to specific nutritional requirements as a result of varying physiological conditions during a lifetime and selecting specific types and optimal amounts of vitamins and minerals for said life stages.Type: GrantFiled: November 24, 1999Date of Patent: December 3, 2002Assignee: Drugtech CorporationInventors: George N. Paradissis, R. Saul Levinson, Robert C. Cuca, Patrick Paul Vanek
-
Patent number: 5869084Abstract: Multi-vitamin and mineral supplements for administration to lactating, non-lactating, and menopausal women, which comprise specific regimens of critical nutritional agents. The supplements are specifically tailored to meet nutritional requirements and maintain a woman's health during each stage of life.Type: GrantFiled: June 7, 1995Date of Patent: February 9, 1999Assignee: K-V Pharmaceuticals Co.Inventors: George N. Paradissis, R. Saul Levinson, Gary Heeter, Robert C. Cuca, Patrick Paul Vanek
-
Patent number: 5858391Abstract: A bioadherent, orally ingestible system, which comprises: a water-in-oil emulsion system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about 1% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.Type: GrantFiled: May 28, 1997Date of Patent: January 12, 1999Assignee: KV Pharmaceutical CompanyInventors: Robert C. Cuca, Keith S. Lienhop, Thomas Charles Riley, Jr., Mitchell I. Kirschner, R. Saul Levinson
-
Patent number: 5730997Abstract: A substantially tasteless liquid phramaceutical delivery system containing an active material and a high osmolarity aqueous system comprising (i) water; (ii) about 20% to about 45% by weight sugar derivative; (iii) about 10% to about 15% by weight hydrogenated maltose syrup; and (iv) about 0% to about 35% by weight polyhydroxy alcohol.Type: GrantFiled: September 11, 1996Date of Patent: March 24, 1998Assignee: KV Pharmaceutical CompanyInventors: Keith S. Lienhop, Robert C. Cuca, Thomas Charles Riley, Jr., R. Saul Levinson
-
Patent number: 5670163Abstract: A bioadherent, orally ingestible system, which comprises: a water-in-oil emulsion system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about 1% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.Type: GrantFiled: May 2, 1995Date of Patent: September 23, 1997Assignee: KV Pharmaceuticals CompanyInventors: Robert C. Cuca, Keith S. Lienhop, Thomas Charles Riley, Jr., Mitchell I. Kirschner, R. Saul Levinson
-
Patent number: 5554380Abstract: A solid or semi-solid bioadherent, orally ingestible drug delivery system containing a water-in-oil system having at least two phases, one phase comprises from about 25% to about 75% by volume of an internal hydrophilic phase and the other phase comprises from about 25% to about 75% by volume of an external hydrophobic phase and wherein the external hydrophobic phase is comprised of three components, a) an emulsifier, b) a glyceride ester and c) a wax material.Type: GrantFiled: May 15, 1995Date of Patent: September 10, 1996Assignee: KV Pharmaceutical CompanyInventors: Robert C. Cuca, Keith S. Lienhop, Thomas C. Riley, Jr., R. Saul Levinson, Mitchell I. Kirschner
-
Patent number: 5494681Abstract: A substantially tasteless pharmaceutical delivery system, which comprises a) an active material; and b) a spatially oriented matrix comprising (i) a wax core material having a melting point within the range of about 50.degree. C. and about 200.degree. C.; and (ii) a regional hydrophobic polymer material and method for making the same.Type: GrantFiled: August 11, 1994Date of Patent: February 27, 1996Assignee: KV Pharmaceutical CompanyInventors: Robert C. Cuca, Ronald S. Harland, Thomas C. Riley, Jr., Yury Lagoviyer, R. Saul Levinson
-
Patent number: 5002777Abstract: A concentrated suspension of calcium carbonate particles in a liquid carrier that is compatible with a capsule shell material. The suspension is pourable and pumpable and may be used to provide antacid capsules.Type: GrantFiled: November 9, 1986Date of Patent: March 26, 1991Assignee: Norcliff Thayer Inc.Inventor: Robert C. Cuca